Ascenta

Researchers Design Promising Cancer Drug

...n for MI-219 and its related molecules. The technology has been licensed by ascenta Therapeutics Inc., which helped fund the study. Wang is a scientific founde...ific adviser, and is the principal investigator on a research contract from ascenta to U-M. More information The National Cancer Institute has more abo...

U-M researchers ID promising new cancer drug

...peutic potential of MI-219 for the treatment of many types of human cancer. ascenta is committed to advancing MI-219, which we have designated AT-219, into hum...un Yang, M.D., Ph.D., senior vice president of research and a co-founder of ascenta Therapeutics, a clinical-stage biopharmaceutical company that has licensed ...

Ascenta in Medical Technology

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

... MALVERN, Pa., May 26 /PRNewswire/ -- ascenta Therapeutics announced today that eleven presentat...h docetaxel, 5-fluorouracil and XRT). About ascenta Therapeutics ascenta Therapeutics, Inc. is a privately-held, clinical-s...

Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer

...osium - MALVERN, Pa., Feb. 27 /PRNewswire/ -- ascenta Therapeutics announced today positive preliminary ...on-small cell lung cancer, is the lead compound in ascenta Therapeutics' portfolio of apoptosis-triggering sm...otential of AT-101," said Mel Sorensen, MD, CEO of ascenta Therapeutics. "The evidence of resistance reversa...

Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting

... SAN DIEGO--(BUSINESS WIRE)--Apr 13, 2007 - ascenta Therapeutics, Inc. announced today that its small ...ang, MD, PhD, Senior Vice President of Research at ascenta Therapeutics and General Manager of Ascenta's R&am...18 and in several poster presentations authored by ascenta personnel and collaborating investigators. In a co...

Ascenta in Biological News

Compound from Chinese medicine shows promise in head and neck cancer

...tongue, mouth, throat and voice box. University of Michigan holds a patent on the negative isomer, (-)-gossypol, and has licensed the technology to ascenta Therapeutics of San Diego, Calif., for commercial development. Wang is one of three U-M Medical School faculty members who founded the company and has...

Ascenta in Biological Technology

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

... MALVERN, Pa., June 1 /PRNewswire/ -- ascenta Therapeutics announced today that promising result...ientific conference" said Mel Sorensen, MD, CEO of ascenta Therapeutics. "The clinical utility of AT-101 is ...rgo apoptosis in various tumor types. About ascenta Therapeutics ...

Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models

...ted - MALVERN, Pa., April 21 /PRNewswire/ -- ascenta Therapeutics announced today that the results of p... apoptotic pathway," said Mel Sorensen, MD, CEO of ascenta Therapeutics. "On the basis of these encouraging ...r models. Other Research Including AT-101 ascenta Therapeutics also announced that researchers from ...

Lixte Biotechnology Holdings Announces New Appointment to Board of Directors

...Director, President and Chief Executive Officer of ascenta Therapeutics. He is a highly experienced leader an...aku, and Hoffmann-La Roche). Dr. Sorensen joined ascenta Therapeutics in August 2004. Under his leadership, in less than three years ascenta was transformed from a 5-person start-up with a si...

Contract Services for Big Pharma and Biotechs Driving Growth and Innovation from Discovery to Clinical Trials

... Pharmaceutical Operations, Alnylam Pharmaceuticals -- RoseAnn Price, Alliance Management, Amgen -- Mel Sorensen, M.D., President & CEO, ascenta Therapeutics, Inc. -- Ahsan Awan, JD, MBA, CRCP, Global CINRG, Inc. -- Gur Roshwalb, MD, VP & Senior Analyst Health Care, Piper Jaffray ...

ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications

...we examine ESR1 gene expression using Gene Logic's ascenta System and demonstrate how this tool can be used t... Materials and Methods The ascenta System is a powerful and reliable gene expression ...r development in drug discovery R&D pipelines. The ascenta System provides readily available gene expression ...